Arana files IND

By Dylan Bushell-Embling
Tuesday, 30 September, 2008

Arana Therapeutics [ASX: AAH] has submitted an IND to the FDA for its candidate ART621 for rheumatoid arthritis.

As part of the IND application, a Phase II dose trial of the anti-TNF drug will be conducted in a multi-centre trial in 200 patients.

Arana expects to begin recruitment for the study later this year, pending approval from the FDA. Quintiles has been named as the contract research manager.

Saliva-based biosensor could improve heart failure detection

Scientists have created a biosensor that can rapidly detect the heart failure biomarker S100A7 in...

Melanoma-causing mutation can lie dormant in healthy skin

Researchers found many examples of the mutation in normal skin, including skin next to a mole and...

Antibiotic for drug-resistant bacteria found in plain sight

The antibiotic in question is an intermediate chemical in the natural process that produces the...

Content from other channels on our network

Webinar: Turning data protection into a business advantage

How mandatory climate reporting is raising the bar for corporate leadership

Partnership doubles medicinal blister pack recycling

Epson Australia releases new Sustainability Impact Report

Specsavers partnership tackles optical waste

Cutting-edge digital health tools putting plastic, silicon and steel to the sword

Electronic prescriptions and how they are used

Webinar: Turning data protection into a business advantage

Breastfeeding challenges healthcare professionals should be prepared to address

Dr Vinod Seetharaman appointed Dedalus ANZ Chief Medical Officer

Meat processing tools on show at IPPE2026

Digital labelling trial proposal in NZ for certain imported food

Large-scale mixing plant for flavour production

Intelligent packaging solutions for the bakery industry

Saputo Dairy Australia launches Individually Quick Frozen shredded mozzarella